Ludwig Maximilian University Hospital, Munich – Germany
About Prof. Dr. Med. Nadia Harbeck
Prof. Dr. Nadia Harbeck is one of the world’s most cited breast cancer specialists with over 30 years of experience as Director of the Breast Center and Chair of Conservative Oncology at LMU University Hospital, Munich. As a leading Surgical Oncology specialist Munich, she is the recipient of the 2023 German Cancer Award and 2020 ESMO Lifetime Achievement Award, with 665+ peer-reviewed publications, h-index 97, and Highly Cited Researcher recognition (2021, 2022, 2023).
- 30+ years of breast cancer and gynaecological oncology experience
- Director — Breast Center and Center for Hereditary Breast and Ovarian Cancer, LMU University Hospital, Munich
- 2023 German Cancer Award; 2020 ESMO Lifetime Achievement Award
- 665+ peer-reviewed publications; h-index 97; Highly Cited Researcher 2021/2022/2023
- ESMO Director of Education (2023–25); Subject Editor ESMO Breast Cancer Guidelines (2022–25)
Qualifications & Credentials
Medical Degrees
- Medical Graduation — Medical School, Ludwig-Maximilians-University, Munich, Germany, 1989
- Approbation (German National Board Certification as Physician) — 4 February 1992
- M.D. (Dr. med.) — Ludwig-Maximilians-University, Munich, Germany, 1 July 1993
- Specialist for Obstetrics and Gynaecology — German National Board Certification, 15 September 1998
- M.D. PhD (Habilitation, Dr. med. habil., Privatdozent) — Technical University of Munich (TUM), 28 December 1998
- Associate Professor for OB&GYN — Technical University of Munich (TUM), 8 December 2003
Fellowships & Special Training
- Specialised Board Certification (Zusatzbezeichnung) and Training Permit (Weiterbildungsberechtigung) for Medical Tumor Therapy
- Genetic Counselling Certification OB&GYN (fachgebundene genetische Beratung)
- Research Group Leader — "Tumor Invasion and Metastasis" (Prof. H. Graeff Lab), TUM, 1999–2002
- Consultant (Oberarzt) for Obstetrics and Gynaecology — TUM, 1 January 2000
Certifications & Accreditations
- German Medical Association — Board Certified Specialist in OB&GYN with Conservative Oncology subspecialty
- LMU Department of Mammology — Certified per DIN EN ISO 9001:2008 and German Cancer Society (DKG)
- European Society for Medical Oncology (ESMO) — Director of Education and Executive Board Member
- German Working Group of Gynaecological Oncology (AGO) — Expert Panel Member
Areas of Expertise
Major Conditions Treated
- Breast Cancer (Early, Locally Advanced, and Metastatic)
- Hereditary Breast and Ovarian Cancer (BRCA-positive)
- Triple-Negative Breast Cancer
- HER2-Positive Breast Cancer
- Hormone Receptor-Positive Breast Cancer
- Breast Cancer in Young Women
- Recurrent and Advanced Breast Cancer
- Gynaecological Oncology (Ovarian, Endometrial, Cervical Cancers)
- Other Solid Tumours (Translational Research)
- Sweat Gland Tumours (Hidradenocarcinoma — published case)
Sub-specialties
- Conservative Oncology / Medical Tumour Therapy: Chair-level expertise in personalised systemic therapy — patients seeking the best Surgical Oncology / Conservative Oncology specialist Munich consult Prof. Harbeck for individualised breast cancer treatment.
- Targeted and Novel Compound Therapy: Principal investigator on numerous breast cancer trials with novel targeted compounds.
- Translational Cancer Research: Prognostic and predictive factors in breast cancer and other malignancies.
- Hereditary Breast and Ovarian Cancer: Director of LMU Center for Hereditary Breast and Ovarian Cancer.
- eHealth and Digital Patient Care: Co-developer of CANKADO international digital patient diary.
Advanced Procedures & Treatments
- Personalised Systemic Therapy for Breast Cancer
- Novel Targeted Compound Therapy
- CDK4/6 Inhibitor Combinations (e.g., abemaciclib + letrozole)
- HER2-Directed Therapy
- Endocrine Therapy
- Immunotherapy for Breast Cancer
- Chemotherapy and Hormonal Therapy
- Genetic Counselling and Risk Assessment (BRCA)
- Multidisciplinary Tumour Board Coordination
- Coordination of Surgical Oncology and Plastic Reconstruction
- Clinical Trial Enrolment and Coordination
- CANKADO Digital Patient Diary Integration
List of Disease and Treatment for which Prof. Dr. Med. Nadia Harbeck can be consulted
Professional Experience
Current Affiliation
- Director, Breast Center and Center for Hereditary Breast and Ovarian Cancer — LMU University Hospital, Munich, Germany (Present)
- Chair for Conservative Oncology, Department of OB&GYN — LMU University Hospital, Munich
- Head, Oncological Therapy & Clinical Trials Unit, Department of OB&GYN — LMU University Hospital, Munich
- Co-Director — West German Study Group (WSG)
- ESMO Director of Education (2023–2025)
- Subject Editor, ESMO Breast Cancer Guidelines (2022–2025)
- Coordinating Editor-in-Chief — Breast Care (peer-reviewed journal)
Past Affiliations
- Head, Breast Center — University of Cologne, Germany, 2009–2011
- Associate Professor for OB&GYN — Technical University of Munich (TUM), 2003 onwards
- Consultant (Oberarzt) for Obstetrics and Gynaecology — TUM, 2000 onwards
- Research Group Leader — "Tumor Invasion and Metastasis" (Prof. H. Graeff Lab), TUM, 1999–2002
- Medical Residency — Women's Hospital, Technical University of Munich
- Medical School — Ludwig-Maximilians-University Munich, 1983–1989
Academic & Research Roles
- ESMO Director of Education (2023–25)
- Subject Editor, ESMO Breast Cancer Guidelines (2022–25)
- ESMO Executive Board Member
- ASCO Annual Meeting Educational Committee Member (2022–2025)
- Expert Panel Member — German AGO Recommendations for Breast Cancer Therapy
- Co-Director — West German Study Group (WSG)
- EORTC Executive Board, Chair of Translational Research Division (2009–2015)
- Coordinating Editor-in-Chief — Breast Care
- Panel/Faculty Member — St. Gallen Consensus on Primary Breast Cancer (since 2015)
- Panel/Faculty Member — Advanced Breast Cancer Consensus (ABC), Lisbon (since 2011)
- Panel/Faculty Member — Breast Cancer in Young Women Conference (BCY) (since 2012)
- ESMO Co-Director — EORTC-ESMO-AACR Methods in Clinical Cancer Research Workshop
- Co-Developer — CANKADO international digital patient diary
Key Achievements
- 30+ years of breast cancer practice and research
- 665+ peer-reviewed publications; h-index 97
- Highly Cited Researcher 2021, 2022, and 2023
- Editor-in-Chief — Breast Care
- Director of LMU Breast Center, ranked among Germany's best
- Principal investigator on numerous landmark breast cancer trials
Awards & Recognitions
National & International Awards
- 2023 German Cancer Award
- 2020 ESMO Lifetime Achievement Award
- 2021 UPO Award for Women in Academy and Research
- 2015 Bavarian Cancer Patient Award
- 2012 Claudia von Schilling Award
- 2008 European Breast Cancer Conference (EBCC) Award (Emmanuel van der Schueren Invited Lecture, Berlin)
- 2002 AGO Schmidt-Matthiesen Award for Gynaecological Oncology
- 2001 American Association for Cancer Research (AACR) Award
- 2001 ASCO Fellowship Merit Award (highest-ranking abstract)
- Highly Cited Researcher — 2021, 2022, 2023
- Keynote Lecture — Danish Cancer Society, Copenhagen, 2010
- Keynote Lecture — German Cancer Congress, Berlin, 2008
- "Innovators in Breast Cancer" — co-chair with G. Hortobagyi (2002–2004)
Professional Memberships
- European Society for Medical Oncology (ESMO) — Executive Board Member, Director of Education
- American Society of Clinical Oncology (ASCO) — Annual Meeting Educational Committee Member
- American Association for Cancer Research (AACR)
- German Cancer Society (Deutsche Krebsgesellschaft, DKG)
- German Working Group of Gynaecological Oncology (AGO)
- EORTC (former Executive Board Member, Translational Research Division Chair)
- West German Study Group (WSG) — Co-Director
Research & Publications
Published Papers (Selected)
- Glatzel V, Tomsitz D, Maurer M, Schneider S, Brunner S, Harbeck N, Heinzerling L. "CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma." Journal der Deutschen Dermatologischen Gesellschaft (DDG). 2025; DOI: 10.1111/ddg.15723.
- 665+ peer-reviewed publications in breast cancer prognostic and predictive factors, novel targeted compounds, individualised treatment strategies, and translational oncology — h-index 97 (full bibliography available on PubMed).
- Coordinating Editor-in-Chief — Breast Care.
- Subject Editor — ESMO Breast Cancer Guidelines (2022–25).
Ongoing Research & Clinical Interests
- Novel targeted compounds in breast cancer
- Individualised treatment strategies
- Prognostic and predictive factors in breast cancer and solid tumours
- eHealth and digital patient care (CANKADO)
- Hereditary breast and ovarian cancer
- International breast cancer consensus development
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Breast Cancer / Conservative Oncology Consultation (Germany) | ₹50,000 – ₹1,00,000 | $600 – $1,200 |
| Comprehensive Breast Cancer Workup (Imaging + Genetics) | ₹4,00,000 – ₹8,00,000 | $4,800 – $9,600 |
| Personalised Chemotherapy (per cycle) | ₹3,50,000 – ₹7,50,000 | $4,200 – $9,000 |
| HER2-Directed Therapy (per cycle) | ₹4,50,000 – ₹9,00,000 | $5,400 – $10,800 |
| CDK4/6 Inhibitor + Endocrine Therapy (monthly) | ₹2,80,000 – ₹6,50,000 | $3,360 – $7,800 |
| Immunotherapy for Breast Cancer (per cycle) | ₹4,50,000 – ₹9,00,000 | $5,400 – $10,800 |
| Genetic Counselling and BRCA Testing | ₹80,000 – ₹2,00,000 | $960 – $2,400 |
| Multidisciplinary Tumour Board Review | ₹60,000 – ₹1,80,000 | $720 – $2,160 |
Frequently Asked Questions
1. What advanced technologies does Dr. Nadia Harbeck use in Surgical Oncology and Breast Cancer treatment?
Prof. Dr. Nadia Harbeck uses advanced personalised systemic therapy, novel targeted compounds, CDK4/6 inhibitor combinations, HER2-directed therapy, endocrine therapy, immunotherapy, integrated genetic counselling and BRCA risk assessment, the CANKADO digital patient diary for eHealth-enabled care, and integrates multidisciplinary tumour board care at the LMU Munich Breast Center.
2. What conditions does Dr. Nadia Harbeck specialize in treating?
Prof. Dr. Nadia Harbeck specialises in early, locally advanced, and metastatic breast cancer of all subtypes (triple-negative, HER2-positive, hormone receptor-positive), hereditary breast and ovarian cancer (BRCA-positive), breast cancer in young women, recurrent and advanced disease, and selected gynaecological oncology cases. As a leading Surgical Oncology specialist Munich, she is widely consulted for personalised systemic therapy and clinical trial enrolment.
3. How do I book an appointment with Dr. Nadia Harbeck?
Appointments with Prof. Dr. Nadia Harbeck can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Nadia Harbeck?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. Nadia Harbeck, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Nadia Harbeck offer second opinions for Surgical Oncology and Breast Cancer cases?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with a 2023 German Cancer Award and 2020 ESMO Lifetime Achievement Award-winning Breast Cancer specialist in Munich, Germany.
University Hospital Rechts der Isar - Germany
